Stockscreener 앱 받기
4.51
2.38%
-0.11
시장 영업 전:
4.53
0.02
+0.44%
전일 마감가:
$4.62
열려 있는:
$4.59
하루 거래량:
1.14M
Relative Volume:
0.86
시가총액:
$582.43M
수익:
$204.17M
순이익/손실:
$-74.00M
주가수익비율:
-7.8095
EPS:
-0.5775
순현금흐름:
$-12.84M
1주 성능:
-2.38%
1개월 성능:
+13.89%
6개월 성능:
-20.88%
1년 성능:
+30.72%
1일 변동 폭
$4.46
$4.69
1주일 범위
$4.31
$4.72
52주 변동 폭
$3.09
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
명칭
Cytek Biosciences Inc
전화
(877) 922-9835
주소
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.51 | 582.43M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
92.11 | 160.44B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
331.45 | 127.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.57 | 106.97B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.65 | 66.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.79 | 52.85B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-09 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-31 | 다운그레이드 | Goldman | Buy → Sell |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-07-19 | 개시 | Raymond James | Mkt Perform |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
모두보기
Cytek Biosciences Inc 주식(CTKB)의 최신 뉴스
Cytek Biosciences announces webinar on accelerating human T-cell biology research - Traders Union
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences - Stock Titan
Cytek Biosciences expands flow cytometry footprint amid growing immunology demand - Ad Hoc News
CTKBCytek BioSciences Inc Latest SEC Filings - Finviz
If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB) - Stock Titan
Cytek Biosciences explores growth paths as investors weigh long-term potential - Ad Hoc News
Cytek Biosciences (CTKB) Edges Higher as Shares Stabilize Near SupportTICK Divergence - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider - Stock Titan
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from Russell 2000 Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to sales forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB - TradingView
CTKB Forecast — Price Target — Prediction for 2027 - TradingView
8EQ Forecast — Price Target — Prediction for 2027 - TradingView
Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB) - TradingView
Cytek Biosciences Announces Chief Legal Officer Transition - The Globe and Mail
Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ) - TradingView
Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary - TradingView
Cytek Biosciences (NASDAQ: CTKB) legal chief exit detailed - Stock Titan
Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 1000 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 Health Care - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 - marketscreener.com
Cytek Biosciences Inc (CTKB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytek Biosciences Stockholders Back Board, Pay and Auditor - The Globe and Mail
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets - Yahoo Finance
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences Inc (CTKB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting By Investing.com - Investing.com South Africa
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting - Investing.com Canada
Cytek Biosciences launches quick reference guide to streamline lab use of cFluor dyes - Traders Union
Cytek Biosciences Inc (CTKB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares - Stock Titan
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes - Stock Titan
Cytek Biosciences Inc (CTKB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytek Biosciences Inc (CTKB) Institutional Confidence - TradingKey
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences, Inc. (CTKB) Presents at Singular Research's Las Vegas Invitational ConferenceSlideshow - Seeking Alpha
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences Inc (CTKB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.00%
0.22%
자본화:
|
볼륨(24시간):